Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Hepatitis C

Cochrane study on direct-acting antivirals is 'fundamentally flawed', says Hepatitis C Trust

The Hepatitis C Trust has criticised a study carried out by the Cochrane Hepato-Biliary Group that cast doubt on the effectiveness of direct-acting antivirals (DAAs) against hepatitis C[1], saying it is “fundamentally flawed”.

The trust, which is a national patient-led charity for hepatitis C, sent a letter to The Guardian, in response to an article it published on the study, expressing its concerns. 

“The Cochrane review analysed clinical trials, which are by nature short term, where the sole purpose was to evaluate the virological efficacy of new antiviral drugs,” says the trust. “The trials were neither designed, nor powered, to assess mortality, so it is not at all surprising that the Cochrane review was unable to identify any impact on mortality.”

In its response, the trust highlights that regulatory authorities and clinicians all recognise that clearing hepatitis C virus reduces mortality and UK-based research has demonstrated that oral antiviral treatment substantially decreases mortality and morbidity in patients with cirrhosis.

It also refers to current data from Public Health England showing that there has already been an 11% reduction in mortality following the introduction of antiviral therapy, as well as a 50% reduction in a need for liver transplantation for chronic hepatitis C infection.

“The real story is one of remarkable, if surprising, success over just a decade, transforming an unpleasant and sometimes fatal disease into one that is readily cured,” it says.

The study has also generated comment on Hep Forums, a discussion area for people who have hepatitis, their friends and family or others with questions about hepatitis and liver health. Forum users criticised the failure of the study to consider long-term natural history data as well as looking at the short-term results in clinical trials, with one respondent describing the study as “pointless”.

“[The study] objective was ‘To assess the benefits and harms of DAAs in people with chronic HCV’ as written in the abstract,” says the respondent. “The report most definitely does not do that. It places the blame on biased, overly short studies; we might place it on the limits the Cochrane Collaboration adopted on which studies got included.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202957

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Popular Medicines

    Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £21.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £520.00Buy now
  • Complete Guide to Medical Writing (The)

    Complete Guide to Medical Writing (The)

    Effectively communicate scientific and medical information with The Complete Guide to Medical Writing.

    £26.00Buy now
  • Pharmacy Case Studies

    Pharmacy Case Studies

    Understand the application of therapeutics in clinical practice with Pharmacy Case Studies. This book helps you to demonstrate the knowledge gained during your studies.

    £32.00Buy now
  • Integrated Pharmacy Case Studies

    Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

    £42.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £52.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • hepatitis c virus test

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.